Ellsworth Advisors LLC Invests $665,000 in Bausch + Lomb Co. (NYSE:BLCO)

Ellsworth Advisors LLC bought a new stake in Bausch + Lomb Co. (NYSE:BLCO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 36,844 shares of the company's stock, valued at approximately $665,000.

A number of other large investors have also added to or reduced their stakes in BLCO. FNY Investment Advisers LLC bought a new stake in Bausch + Lomb in the fourth quarter worth $72,000. King Street Capital Management L.P. purchased a new stake in Bausch + Lomb during the 3rd quarter valued at about $14,122,000. Barclays PLC purchased a new stake in Bausch + Lomb during the 3rd quarter valued at about $5,797,000. Gordian Capital Singapore Pte Ltd bought a new position in Bausch + Lomb during the 3rd quarter worth approximately $289,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Bausch + Lomb in the 3rd quarter worth approximately $555,000. Hedge funds and other institutional investors own 11.07% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Wells Fargo & Company cut their target price on shares of Bausch + Lomb from $26.00 to $24.00 and set an "overweight" rating on the stock in a report on Thursday. Needham & Company LLC restated a "hold" rating on shares of Bausch + Lomb in a research report on Thursday, October 31st. Bank of America reaffirmed an "underperform" rating and set a $18.00 price objective on shares of Bausch + Lomb in a research note on Thursday, December 12th. Evercore ISI raised Bausch + Lomb from an "in-line" rating to an "outperform" rating and raised their target price for the stock from $19.00 to $25.00 in a research note on Tuesday, October 15th. Finally, Citigroup lowered Bausch + Lomb from a "buy" rating to a "neutral" rating and lowered their price target for the company from $24.00 to $22.00 in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $20.42.

Bausch + Lomb Stock Down 0.4 %

Bausch + Lomb stock traded down $0.08 on Monday, hitting $17.36. 711,200 shares of the stock traded hands, compared to its average volume of 326,313. The business's fifty day simple moving average is $18.77 and its 200 day simple moving average is $18.04. The firm has a market cap of $6.12 billion, a P/E ratio of -16.54, a price-to-earnings-growth ratio of 1.23 and a beta of 0.47. The company has a current ratio of 1.57, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. Bausch + Lomb Co. has a 1 year low of $13.16 and a 1 year high of $21.69.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.16 by $0.01. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. The company had revenue of $1.20 billion during the quarter, compared to analysts' expectations of $1.17 billion. During the same period last year, the company posted $0.22 EPS. Bausch + Lomb's revenue was up 18.8% on a year-over-year basis. As a group, sell-side analysts forecast that Bausch + Lomb Co. will post 0.6 earnings per share for the current year.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.